Transplant diagnostic firm Verici DX and Thermo Fisher Scientific have signed an exclusive global licensing and commercialization agreement to develop a pre-transplant prognostic test for early kidney rejection risk assessment.

Pillar Biosciences said on Thursday that it has acquired a nonexclusive license to high-throughput screening-related intellectual property from Dutch ag-bio firm KeyGene.

Natera reported after the close of market Tuesday year-over-year revenue gains of approximately 26 percent for the fourth quarter of 2022 and 31 percent for the full year.

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2022.

Qiagen reported on Tuesday that its fourth quarter sales declined 14 percent with an expected decrease in COVID-related sales offset by increased sales in the firm's non-COVID portfolio.

DiaSorin reported Thursday its third quarter revenues declined 5 percent year over year with waning COVID-19 testing demand, despite rising revenues across its other diagnostics businesses.

Danaher's diversification of its business conglomerate has led to increased stability and second quarter revenue growth in the face of headwinds, company executives said on Thursday

Roche on Thursday reported its Diagnostics division revenues grew 10 percent year over year in the first half of the year but said that it expects the momentum from COVID-19 testing-related sales to slow throughout the rest of the year.

Quidel on Thursday said that it expects its first quarter revenues to nearly triple year over year, primarily on sales of COVID-19 testing products.

DiaSorin on Wednesday said that its 2021 revenues rose 41 percent year over year.